A California state bill claiming that personal genomics companies should be governed by rules different from other diagnostic tests has sparked a debate over the business of selling genomic information. The bill (SB 482), sponsored by California state senator Alex Padilla and Mountain View, California–based personal genomics firm 23andme, argues that companies that do not perform wet lab services, so-called post-CLIA (clinical laboratory improvement amendments) bioinformatics firms, should not be subject to the same rules as those that do. The companies argue that the services don't fit the current regulatory framework. Padilla, however, denies the new bill is an attempt to exempt them from regulation. “It's exactly the opposite,” he says, pointing to provisions in the bill requiring companies to contract CLIA-laboratories, for instance. The privacy provisions outlined in the bill, however, don't go far enough, the American Civil Liberties Union (ACLU) of California points out. Gail Javitt of Johns Hopkins University's Genetics and Public Policy Center in Baltimore also notes: “CLIA also addresses how laboratories select tests and communicate tests results. There's more to laboratory oversight than the wet-lab portion,” she says. The bill awaits approval by the state's judiciary committee before going up for a vote. In the absence of federal regulations on this issue, more states might consider similar legislation.